Notícias

Organic growth hit a three-year high as AI and robotics demand accelerated.

Novanta (NasdaqGS:NOVT) has closed its acquisition of RiverPoint Medical, the largest deal in the company's history. The transaction expands Novanta's exposure to medical end markets and is expected to be immediately accretive to revenue growth and margins. Management is accelerating a manufacturing restructuring plan alongside the RiverPoint integration, with potential long-term effects on efficiency and profitability. For investors watching how medical technology companies scale up and...

Novanta Inc (NOVT) delivered robust Q2 2026 results with 9% organic growth, record cash flow, and raised full-year guidance following the Riverpoint Medical acquisition.

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

Novanta (NOVT) delivered earnings and revenue surprises of +7.23% and +1.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) will be announcing earnings results this Monday after market close. Here’s what to expect.

This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings.

Novanta Inc (NOVT) reports impressive revenue and bookings growth, driven by AI and robotics, while navigating cost pressures and geopolitical uncertainties.

Novanta (NOVT) just posted first quarter results that beat earnings and revenue expectations, with sales of US$257.71 million and forward guidance above analyst estimates, marking a shift after earlier quarters of missed forecasts. See our latest analysis for Novanta. The strong first quarter beat and improved guidance appear to be feeding into momentum, with the share price up 11.8% over the past month and a year to date share price return of 26%. This is despite the 3 year total shareholder...

Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive

Moby summary of Novanta Inc.'s Q1 2026 earnings call

Novanta (NOVT) delivered earnings and revenue surprises of +3.85% and +1.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ouster (OUST) delivered earnings and revenue surprises of +19.36% and +6.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?